CS1002

CStone Pharmaceuticals · Phase 1 active Small molecule

At a glance

Generic name	CS1002
Also known as	anti-CTLA 4
Sponsor	CStone Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CS1002 CI brief — competitive landscape report
CS1002 updates RSS · CI watch RSS
CStone Pharmaceuticals portfolio CI